57 studies found for:    "infantile-onset spinocerebellar ataxia" OR "Spinocerebellar Ataxias"
Show Display Options
Rank Status Study
1 Recruiting Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 6
Intervention:
2 Recruiting Dalfampridine and Gait in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxias Type 1;   Spinocerebellar Ataxias Type 2;   Spinocerebellar Ataxias Type 3;   Spinocerebellar Ataxias Type 6
Interventions: Drug: Dalfampridine;   Drug: Placebo
3 Recruiting Biomarkers in Autosomal Dominant Cerebellar Ataxia
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia, Autosomal Recessive 3;   Episodic Ataxia, Type 7
Intervention: Other: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
4 Completed Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxia
Intervention:
5 Active, not recruiting Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Conditions: Spinocerebellar Ataxias;   Spastic Paraplegias
Intervention:
6 Completed Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
Condition: Spinocerebellar Ataxia Type I
Intervention: Drug: Lithium Carbonate
7 Completed Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Conditions: Spinocerebellar Ataxia Type 3;   Machado Joseph Disease
Interventions: Drug: Lithium Carbonate;   Drug: Placebo
8 Recruiting Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia Type 3
Intervention: Biological: IVIG
9 Completed Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
Condition: SPINOCEREBELLAR ATAXIA 2
Intervention: Drug: LITHIUM CARBONATE
10 Completed Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: varenicline;   Drug: placebo
11 Active, not recruiting RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
Condition: Spinocerebellar Ataxias
Intervention:
12 Withdrawn Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: Placebo;   Drug: Sodium Phenylbutyrate
13 Completed A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373;   Drug: Placebo
14 Completed Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Intervention: Drug: KPS-0373
15 Completed Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)
Condition: Hereditary Ataxia
Intervention:
16 Completed High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
Condition: Spinocerebellar Degenerations
Intervention: Drug: high-dose intravenous immunoglobulin (IVIG)
17 Completed Coenzyme Q10 in Adult-Onset Ataxia
Condition: Sporadic Ataxia
Interventions: Drug: Placebo (sugar pill);   Drug: Coenzyme Q10
18 Completed A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: SCD
Interventions: Drug: KPS-0373;   Drug: Placebo
19 Enrolling by invitation 4-Aminopyridine in Episodic Ataxia Type 2
Condition: Episodic Ataxia Type 2
Interventions: Drug: 4AP;   Drug: Placebo
20 Unknown  Characteristics of Episodic Ataxia Syndrome
Conditions: Episodic Ataxia Syndrome;   Cerebellar Diseases
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years